Clinical Trials

AstraZeneca and Eli Lilly and Company (Lilly) announced they have received US FDA Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in Phase III clinical trial....

KalVista Pharmaceuticals announced the dosing of the first subject in a first-in-human clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally delivered KVD818 in healthy volunteers. A KalVista discovery, KVD818 is a novel, potent,...

At the Alzheimer's Association International Conference 2016 (AAIC 2016), held in Toronto, Canada, researchers reveal how a drug called LMTX shows promise for halting the formation of tau tangles. Alzheimer's disease is estimated to affect 5.4...

AstraZeneca announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd-line treatment in patients with KRAS mutation-positive (KRASm) locally-advanced or metastatic non-small cell lung cancer (NSCLC). ...

Antibe Therapeutics Inc. is pleased to announce the successful completion of its phase 2 clinical trial of ATB-346 in osteoarthritis (“OA”). Twelve patients with OA of the knee were treated once daily for 10 days with ATB-346 at a...

ClinicalRM will again deploy its boots-on-the-ground approach to fighting Ebola Virus Disease (EVD) with an expanded access protocol for ZMappTM, an investigational treatment for EVD, in Africa and the U.S. ClinicalRM will perform as subcontractor under...

Inovio Pharmaceuticals, Inc announced the dosing of the first subject in its multi-center phase I trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700). In addition to the previously announced US FDA approval for the conduct of the study, Health...